ARCHIVES

News Analysis by Keith Baggerly: Duke Trials Went On Despite FDA Statements

This article is from The Cancer Letter archive.

Vol. 38 No. 04 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine

August 31, 2012

Move Starts To Strip Anticancer Drug Regulation From FDA After New Charges It Is Delaying INDs

October 15, 1976

In Brief: President OK’s Mammography Standard Publication, CDC State Grants Increase

January 7, 1994

Funding Opportunities

December 13, 2002

ASC Survey Leads to Strategic Plan Development, Office In Washington

June 9, 1989

Phase III Ramucirumab Trial Fails Primary Endpoint of PFS

October 25, 2013